Ann: FIELD TRIALS COMPLETED , page-8

Yes clyde, I had thought that too but couldnt find a direct preference for US companies in the material I've looked at. That is not to say it isnt a real thing, just not stated.

However, the second stated goal from their website squarely fits the profile of ArtiMist. Copied below.

If you look through their recent grants list for malaria related activity there is a solid stream of money to various NON-US universities and health researchers(Dakar, Imperial College London, Barcelona, France) as well as US researchers. Seems largely in fairly equal parts. So research dollars seem fairly flung.

The rubber will hit the road when a value judgement on need must be made against the goal they have for a vaccine by 2025. Note the UN has goals to "rollback" malaria in Africa by 2015.See http://www.rollbackmalaria.org/ , so the timing for EMS is perfect.

John

----------------------
from: http://www.gatesfoundation.org/topics/Pages/malaria.aspx

Our Approach: Malaria
Develop malaria vaccines
We believe a preventive vaccine would provide the best long-term hope to defeat malaria, and would be especially beneficial for those at greatest risk: infants, children, and pregnant women. Our goal is to ensure the development and launch of a safe, effective, and affordable vaccine against malaria by 2025.

Develop more effective and affordable drugs and diagnostics
Though current treatments for malaria are highly effective, they are expensive for people in poor countries and malaria parasites are becoming increasingly resistant to them. Our strategy supports the development and delivery of new malaria drugs, particularly for treating acute malaria in at-risk populations, including infants, young children, and pregnant women.

Develop new tools to control mosquitoes
Insecticide-treated bed nets and indoor spraying of insecticides in homes has been a successful approach for controlling mosquitoes. However, mosquitoes are becoming more resistant to today’s insecticides. We’re supporting the development of new active ingredients and products that combat insecticide resistance.

Research the effectiveness of malaria interventions
Better data are needed to tell us what works in malaria control. We’re supporting efforts to evaluate malaria control interventions and study how to best deliver such interventions.

Advocate for policies and financing
The last decade has witnessed major new investments in malaria control efforts around the world. However, continued investments and policies are needed to maintain and expand access to tools for prevention and treatment, and to develop new strategies and interventions to stay ahead of the emerging resistance to drugs and insecticides. We’re working to advocate for increased funding and effective policies for malaria research and control.